These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery of potent macrocyclic HCV NS5A inhibitors. Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743 [TBL] [Abstract][Full Text] [Related]
5. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi Link JO; Taylor JG; Trejo-Martin A; Kato D; Katana AA; Krygowski ES; Yang ZY; Zipfel S; Cottell JJ; Bacon EM; Tran CV; Yang CY; Wang Y; Wang KW; Zhao G; Cheng G; Tian Y; Gong R; Lee YJ; Yu M; Gorman E; Mogalian E; Perry JK Bioorg Med Chem Lett; 2019 Aug; 29(16):2415-2427. PubMed ID: 31230974 [TBL] [Abstract][Full Text] [Related]
6. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258 [TBL] [Abstract][Full Text] [Related]
7. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. Kang IJ; Hsu SJ; Yang HY; Yeh TK; Lee CC; Lee YC; Tian YW; Song JS; Hsu TA; Chao YS; Yueh A; Chern JH J Med Chem; 2017 Jan; 60(1):228-247. PubMed ID: 27966956 [TBL] [Abstract][Full Text] [Related]
8. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559 [TBL] [Abstract][Full Text] [Related]
9. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665 [TBL] [Abstract][Full Text] [Related]
10. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742 [TBL] [Abstract][Full Text] [Related]
11. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development. Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003 [TBL] [Abstract][Full Text] [Related]
12. Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions. Yu W; Tong L; Selyutin O; Chen L; Hu B; Zhong B; Hao J; Ji T; Zan S; Yin J; Ruck RT; Curry S; McMonagle P; Agrawal S; Rokosz L; Carr D; Ingravallo P; Bystol K; Lahser F; Liu R; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA J Med Chem; 2018 May; 61(9):3984-4003. PubMed ID: 29681153 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core. Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390 [TBL] [Abstract][Full Text] [Related]
14. Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320 [TBL] [Abstract][Full Text] [Related]
16. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194 [TBL] [Abstract][Full Text] [Related]
17. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity. Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013 [TBL] [Abstract][Full Text] [Related]
18. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). Wagner R; Randolph JT; Patel SV; Nelson L; Matulenko MA; Keddy R; Pratt JK; Liu D; Krueger AC; Donner PL; Hutchinson DK; Flentge C; Betebenner D; Rockway T; Maring CJ; Ng TI; Krishnan P; Pilot-Matias T; Collins C; Panchal N; Reisch T; Dekhtyar T; Mondal R; Stolarik DF; Gao Y; Gao W; Beno DA; Kati WM J Med Chem; 2018 May; 61(9):4052-4066. PubMed ID: 29653491 [TBL] [Abstract][Full Text] [Related]
19. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. Belema M; Meanwell NA J Med Chem; 2014 Jun; 57(12):5057-71. PubMed ID: 24749835 [TBL] [Abstract][Full Text] [Related]
20. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. DeGoey DA; Randolph JT; Liu D; Pratt J; Hutchins C; Donner P; Krueger AC; Matulenko M; Patel S; Motter CE; Nelson L; Keddy R; Tufano M; Caspi DD; Krishnan P; Mistry N; Koev G; Reisch TJ; Mondal R; Pilot-Matias T; Gao Y; Beno DW; Maring CJ; Molla A; Dumas E; Campbell A; Williams L; Collins C; Wagner R; Kati WM J Med Chem; 2014 Mar; 57(5):2047-57. PubMed ID: 24400777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]